SCHEMBL1815334

SCHEMBL1815334

COc1ccc(-c2cc(C(=O)N[C@]3(C(=O)O)CC[C@H](C)CC3)ccc2OC2CC(F)(F)C2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 4/20 0.45
▸ TAS1R3 Q7RTX0 2/20 0.39
▸ TAS1R1 Q7RTX1 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ RECQL P46063 1/20 0.39
▸ GPR132 Q9UNW8 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PDE4A P27815 3/20 0.37
▸ PDE4B Q07343 3/20 0.37
▸ PDE4C Q08493 3/20 0.37
▸ PDE4D Q08499 3/20 0.37
▸ BCL9 O00512 7/20 0.37
▸ CTNNB1 P35222 7/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845266 1.00 LPAR1 (0.45) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL1815336 1.00 LPAR1 (0.45) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL1811907 0.93 LPAR1 (0.40) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL13464508 0.92 LPAR1 (0.51) LPAR1TAS1R3TAS1R1ALDH1A1LMNA
SCHEMBL1810388 0.82 PDE4B (0.46) TAS1R3TAS1R1ALDH1A1LMNAKMT2A
SCHEMBL1810726 0.81 LPAR1 (0.44) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL6845326 0.81 LPAR1 (0.44) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL1810724 0.81 LPAR1 (0.44) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL1810725 0.81 LPAR1 (0.44) LPAR1TAS1R3TAS1R1ALDH1A1MAPT
SCHEMBL1810988 0.81 KMT2A (0.43) TAS1R3TAS1R1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496556-B1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2018-12-26 — — EP disclosed
US-9018383-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2015-04-28 — — US disclosed
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2014-03-27 — — US disclosed
US-8618304-B2 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals SANOFI (FR) 2013-12-31 — — US disclosed
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-10-18 — — US disclosed
EP-2496556-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI (FR) 2012-09-12 — — EP disclosed
WO-2011053948-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264790-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 LPAR1 4/4885TAS1R3 3781/4885TAS1R1 3419/4885
US-20140088158-A1 ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS LPAR2, LIPG, EDF1 LPAR1 4/4885TAS1R3 3781/4885TAS1R1 3419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback